-

Agilent Inspires at SLAS2023, Highlighting Innovative Automated Workflow Solutions

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will highlight a suite of automated laboratory workflow solutions at the SLAS2023 International Conference and Exhibition held February 25 through March 1 in San Diego. Agilent is also honored to receive an SLAS Lab of the Future designation, signifying going beyond automated instrumentation and bringing complete integrated automated workflow solutions to the lab. Agilent is a leader in advancing automation solutions to help customers improve efficiency and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

There is growing pressure on labs to deliver high-quality results while streamlining operations, reducing costs, and increasing revenue. Agilent’s modular automation solutions address a wide array of workflows, including cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry in non-regulated and regulated environments. Automating processes and workflows allows scientists and lab technicians to use their time more effectively and focus on higher-value, more productive tasks. Automated sample preparation is streamlined, more accurate, enhances reproducibility, and ultimately enables more confident decisions.

SLAS attendees are invited to visit exhibit booth #1811 and learn more about Agilent’s complete automation portfolio, including these innovations:

Lars Kristiansen, general manager of Agilent’s Automation Solutions Business, commented, “SLAS is a great opportunity for us to demonstrate how our automation solutions continue to redefine what’s possible through our commitment to creating differentiated workflow solutions to advance automation for our customers with critical product innovations.”

“Agilent’s modular workflow solutions are designed to integrate easily and work together seamlessly to reduce or eliminate the risk of human errors. Agilent’s Digital Lab enables and automates these activities to keep end users focused on their science. We look forward to sharing more information at SLAS this year,” Kristiansen added.

Product tutorials will be held on Monday, February 27, and Tuesday, February 28, and a Solutions Spotlight session on Tuesday, February 28, entitled An integrated live-cell imaging system for automated high-throughput analysis of 2D cell migration and chemotaxis. To learn more about these educational events, visit Agilent booth #1811. Agilent is proud to be a diamond sponsor of SLAS2023.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Completes Acquisition of Biocare Medical

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st...

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...
Back to Newsroom